Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome
Barbara Vannata(Institute of Oncology Research), Emanuele Zucca(Università della Svizzera italiana), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Maria Cristina Pirosa(Institute of Oncology Research), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Annarita Conconi(Ospedale degli Infermi), Luciano Cascione(Institute of Oncology Research), Jonas Winkler(Institute of Oncology Research), Anastasios Stathis(Princess Margaret Cancer Centre), Gloria Margiotta Casaluci(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alden A. Moccia(BC Cancer Agency), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luca Nassi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 20
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791